FDA Approves Neoadjuvant/Adjuvant Opdivo for Resectable NSCLC

The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors ≥4 cm and/or node-positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements. 

Efficacy was evaluated in CHECKMATE-77T (ClinicalTrials.gov. Identifier: NCT04025879), a